BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

BioCryst Pharmaceuticals (BCRX) has granted stock options and restricted stock units (RSUs) to eight newly-hired employees as employment inducements. The compensation committee approved options to purchase 22,575 shares and RSUs covering 27,550 shares of common stock, effective January 31, 2025.

The stock options were granted at an exercise price of $7.90 per share, matching the closing price on the grant date. Both options and RSUs will vest in four equal annual installments, starting from the one-year anniversary of the grant date, contingent on continued employment. The stock options have a 10-year term and are subject to BioCryst's Inducement Equity Incentive Plan terms.

RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted eight newly-hired employees stock options to purchase an aggregate of 22,575 shares, and restricted stock units (RSUs) covering an aggregate of 27,550 shares, of BioCryst common stock. The options and RSUs were granted as of January 31, 2025, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $7.90 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term. The options and RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO^® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

FAQ

How many shares of BCRX stock options were granted to new employees in January 2025?

BioCryst granted stock options to purchase 22,575 shares to eight newly-hired employees as of January 31, 2025.

What is the exercise price for BCRX stock options granted on January 31, 2025?

The stock options were granted with an exercise price of $7.90 per share, equal to BCRX's closing price on January 31, 2025.

How many RSUs did BCRX grant to new employees in January 2025?

BioCryst granted restricted stock units (RSUs) covering 27,550 shares to eight newly-hired employees.

What is the vesting schedule for BCRX's January 2025 stock options and RSUs?

Both the stock options and RSUs vest in four equal annual installments, beginning on the one-year anniversary of the grant date.